Market News & Trends
Evaxion to Unveil Potentially Groundbreaking AI-Immunology Precision Cancer Vaccine Concept
Evaxion Biotech A/S recently announced the presentation of its novel precision vaccine concept at the 65th American Society of Hematology (ASH) Annual Meeting, taking place…
Roivant & Priovant Announce Results From Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
Roivant and Priovant recently announced the Phase 2 study evaluating oral brepocitinib in adult patients with moderate to severe active lupus did not meet its…
GRI Bio Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis
GRI Bio, Inc. recently announced the US FDA has cleared the company’s Investigational New Drug (IND) application for GRI-0621 for the treatment of IPF. The…
Biodexa Enters Agreements to Acquire Exclusive Worldwide License to a Phase 2 Ready Asset for Type 1 Diabetes
Biodexa Pharmaceuticals PLC recently announced it has entered into an agreement for the assignment of Adhera Therapeutics, Inc.’s rights to tolimidone (formerly coded MLR-1023) under an exclusive,….
ADvantage Therapeutics Commences Enrollment for Phase 2b Clinical Trial for Alzheimer’s Disease Treatment
ADvantage Therapeutics, Inc. recently announced the first patient enrolled in the company’s European Phase 2b clinical trial on its lead candidate AD04 for the treatment…
Alladapt Immunotherapeutics Receives FDA Fast Track Designation for the Treatment of Mono- and Multi-Food Allergies
Alladapt Immunotherapeutics, Inc. recently announced that ADP101, its investigational multi-food oral immunotherapy (mOIT) designed to simultaneously treat allergy to one or more of the world’s…
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion & Enrollment of First Patient Into Phase 3 Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
Aerovate Therapeutics, Inc. recently announced the Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) Phase 2b/Phase 3 study evaluating AV-101,…
Symbiosis Pharmaceutical Services Granted MHRA License Following Significant Investment
Symbiosis Pharmaceutical Services has recently launched new in-house analytical and microbiological capabilities to enable testing of small molecule, biological, and Advanced Therapeutic Medicinal Products (ATMP)…
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
Zevra Therapeutics, Inc. recently announced the completion of its acquisition of Acer Therapeutics Inc., which marks a significant step forward in executing Zevra’s strategy to become….
Hovione Acquires ExtremoChem & Its Portfolio of Proprietary Sugars to Support Customers With Stabilization & Delivery of Biopharmaceuticals
Hovione, the specialist integrated CDMO and the leader in spray drying and particle engineering, has recently announced it has acquired ExtremoChem Lda (ExtremoChem), an innovative start-up company focused on….
Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease to EMA
Anavex Life Sciences Corp. recently announced representatives of Anavex met with team members of the European Medicines Agency (EMA). These meetings discussed the debilitating pathology…
Yamo Pharmaceuticals Enrolls Final Patient in Phase 2 Study Evaluating L1-79 to Treat the Core Symptoms of Autism Spectrum Disorder
Yamo Pharmaceuticals LLC recently announced it has completed enrollment in its Phase 2 study evaluating L1-79 in adolescents and young adults with autism spectrum disorder…
Boehringer Ingelheim Expands Usage of Genedata Biologics to DMPK Operations
Genedata recently announced Boehringer Ingelheim has expanded usage of the Genedata platform to include the Drug Metabolism and Pharmacokinetics (DMPK) group in the US. The…
Medicenna Announces Compelling Survival Benefit From Phase 2b Study of Bizaxofusp in Recurrent Gliobastoma
Medicenna Therapeutics Corp. recently announced a poster presentation and an oral summary highlighting longer term follow up results from the Phase 2b clinical trial of…
Uppsala University Hospital & Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients With Type 1 Diabetes
Sana Biotechnology, Inc. and Uppsala University Hospital in Sweden recently announced the Swedish Medical Products Agency has authorized Uppsala University’s Clinical Trial Application (CTA) to…
Ichor Life Sciences Announces Launch of Ichor Clinical Trial Services
Ichor Life Sciences recently announced the launch of Ichor Clinical Trial Services. With the founding of Ichor Clinical, the company is now able to serve…
Ajinomoto to Acquire Forge Biologics for $620 Million
Acquisition extends global capabilities in AAV and plasmid gene therapy manufacturing for Ajinomoto, Co. Inc., diversifying and strengthening their current contract development and manufacturing services….
Symbio & Dow Group Merge With Proinnovera to Form Leading Dermatology CRO, Symbio Proinnovera
The newly announced merger of NY-headquartered Symbio LLC and CA-headquartered Dow Development Laboratories LLC with Munster (Germany)-based Proinnovera will form Symbio Proinnovera, creating one of…
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer
Apollomics Inc. recently announced its partner in China, Avistone Biotechnology Co. Ltd., received conditional approval from the National Medical Products Administration (NMPA) of China for…
Prange Group & Adragos Pharma to Acquire Fresenius Kabi’s Manufacturing Site
Prange Group and its affiliate Adragos Pharma have announced the signing of definitive agreements with Fresenius Kabi for the acquisition of the leading sterile pharmaceutical production site in….
